Merck CEO Says Covid-19 Vaccine at Least a Year Away

The transcript discusses the challenges and considerations in vaccine development, focusing on federal funding, timelines, and safety. It highlights the importance of scientific rigor and outlines the phases of human trials, emphasizing the need for safety and adherence to FDA guidelines.

What is the speaker's perspective on the funding received from the federal government?

• They are worried about the funding.

• They think it will be sufficient when needed.

• They are indifferent about the funding.

• They believe it gives them an unfair advantage.

When does the speaker expect to start human testing for their vaccines?

• In the middle of next year

• At the start of next year

• By the end of this year

• By the end of next year

What is the speaker's stance on the urgency of vaccine development?

• They think urgency is not important.

• They are unsure about the urgency.

• They believe safety should never be compromised.

• They prioritize speed over safety.

What does the FDA require before approving a vaccine for emergency use?

• Three months of data observation

• Immediate approval without data

• Six months of data observation

• One year of data observation

How long does the speaker suggest it might take to have a vaccine ready?

• More than four years

• Approximately one year

• Around two years

• Less than six months